These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34965883)

  • 1. Hereditary angioedema due to C1 inhibitor deficiency: real-world experience from the Icatibant Outcome Survey in Spain.
    Guilarte M; Sala-Cunill A; Baeza ML; Cabañas R; Hernández MD; Ibañez E; de Larramendi CH; Lleonart R; Lobera T; Marqués L; de San Pedro BS; Botha J; Andresen I; Caballero T;
    Allergy Asthma Clin Immunol; 2021 Dec; 17(1):137. PubMed ID: 34965883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Management of patients with hereditary angioedema in Germany: comparison with other countries in the Icatibant Outcome Survey.
    Maurer M; Bork K; Martinez-Saguer I; Aygören-Pürsün E; Botha J; Andresen I; Magerl M
    J Eur Acad Dermatol Venereol; 2019 Jan; 33(1):163-169. PubMed ID: 30176179
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Icatibant Outcome Survey: experience of hereditary angioedema management from six European countries.
    Caballero T; Aberer W; Longhurst HJ; Maurer M; Zanichelli A; Perrin A; Bouillet L; Andresen I;
    J Eur Acad Dermatol Venereol; 2017 Jul; 31(7):1214-1222. PubMed ID: 28370444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Icatibant use in Brazilian patients with hereditary angioedema (HAE) type 1 or 2 and HAE with normal C1-INH levels: findings from the Icatibant Outcome Survey Registry Study.
    Grumach AS; Henriques MT; Bardou MLD; Pontarolli DA; Botha J; Correa M;
    An Bras Dermatol; 2022; 97(4):448-457. PubMed ID: 35654647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hereditary angioedema with normal C1 inhibitor in a French cohort: Clinical characteristics and response to treatment with icatibant.
    Bouillet L; Boccon-Gibod I; Launay D; Gompel A; Kanny G; Fabien V; Fain O;
    Immun Inflamm Dis; 2017 Mar; 5(1):29-36. PubMed ID: 28250922
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of hereditary angioedema with icatibant: efficacy in clinical trials versus effectiveness in the real-world setting.
    Maurer M; Longhurst HJ; Fabien V; Li HH; Lumry WR
    Allergy Asthma Proc; 2014; 35(5):377-81. PubMed ID: 25198193
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world outcomes in hereditary angioedema: first experience from the Icatibant Outcome Survey in the United Kingdom.
    Longhurst HJ; Dempster J; Lorenzo L; Buckland M; Grigoriadou S; Symons C; Bethune C; Fabien V; Bangs C; Garcez T
    Allergy Asthma Clin Immunol; 2018; 14():28. PubMed ID: 30127805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Icatibant Outcome Survey: 10 years of experience with icatibant for patients with hereditary angioedema.
    Maurer M; Aberer W; Caballero T; Bouillet L; Grumach AS; Botha J; Andresen I; Longhurst HJ;
    Clin Exp Allergy; 2022 Sep; 52(9):1048-1058. PubMed ID: 35861129
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparing acquired angioedema with hereditary angioedema (types I/II): findings from the Icatibant Outcome Survey.
    Longhurst HJ; Zanichelli A; Caballero T; Bouillet L; Aberer W; Maurer M; Fain O; Fabien V; Andresen I;
    Clin Exp Immunol; 2017 Apr; 188(1):148-153. PubMed ID: 27936514
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis are responsive to icatibant: findings from the Icatibant Outcome Survey.
    Aberer W; Maurer M; Bouillet L; Zanichelli A; Caballero T; Longhurst HJ; Perrin A; Andresen I;
    Allergy Asthma Clin Immunol; 2017; 13():31. PubMed ID: 28690642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Icatibant Outcome Survey in Patients with Hereditary Angioedema: Experience in Israel Compared with Other Countries.
    Toubi E; Kivity S; Graif Y; Reshef A; Botha J; Andresen I
    Isr Med Assoc J; 2018 Apr; 20(4):227-232. PubMed ID: 29629730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of HAE Attacks in the Icatibant Outcome Survey: An Analysis of Icatibant Self-Administration versus Administration by Health Care Professionals.
    Hernández Fernandez de Rojas D; Ibañez E; Longhurst H; Maurer M; Fabien V; Aberer W; Bouillet L; Zanichelli A; Caballero T;
    Int Arch Allergy Immunol; 2015; 167(1):21-8. PubMed ID: 26112099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of characteristics associated with reinjection of icatibant: Results from the icatibant outcome survey.
    Longhurst HJ; Aberer W; Bouillet L; Caballero T; Fabien V; Zanichelli A; Maurer M;
    Allergy Asthma Proc; 2015; 36(5):399-406. PubMed ID: 26314822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of hereditary angioedema in Japan: Focus on icatibant for the treatment of acute attacks.
    Hide M; Horiuchi T; Ohsawa I; Andresen I; Fukunaga A
    Allergol Int; 2021 Jan; 70(1):45-54. PubMed ID: 32919903
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Variability of disease activity in patients with hereditary angioedema type 1/2: longitudinal data from the Icatibant Outcome Survey.
    Maurer M; Caballero T; Aberer W; Zanichelli A; Bouillet L; Bygum A; Grumach AS; Botha J; Andresen I; Longhurst HJ;
    J Eur Acad Dermatol Venereol; 2021 Dec; 35(12):2421-2430. PubMed ID: 34506666
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment.
    Maurer M; Aberer W; Bouillet L; Caballero T; Fabien V; Kanny G; Kaplan A; Longhurst H; Zanichelli A;
    PLoS One; 2013; 8(2):e53773. PubMed ID: 23390491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Icatibant treatment for acquired C1-inhibitor deficiency: a real-world observational study.
    Zanichelli A; Bova M; Coerezza A; Petraroli A; Triggiani M; Cicardi M
    Allergy; 2012 Aug; 67(8):1074-7. PubMed ID: 22686628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Icatibant Outcome Survey: treatment of laryngeal angioedema attacks.
    Longhurst HJ; Aberer W; Bouillet L; Caballero T; Maurer M; Fabien V; Zanichelli A;
    Eur J Emerg Med; 2016 Jun; 23(3):224-7. PubMed ID: 27116379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST-2 open-label study.
    Baş M; Greve J; Hoffmann TK; Reshef A; Aberer W; Maurer M; Kivity S; Farkas H; Floccard B; Arcoleo F; Martin L; Sitkauskiene B; Bouillet L; Schmid-Grendelmeier P; Li H; Zanichelli A
    Allergy; 2013 Nov; 68(11):1452-9. PubMed ID: 24111645
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Subcutaneous Icatibant for the Treatment of Hereditary Angioedema Attacks: Comparison of Home Self-Administration with Administration at a Medical Facility.
    Otani IM; Lumry WR; Hurwitz S; Li HH; Craig TJ; Holtzman NS; Iandoli MI; Tucker J; Riedl MA; Zuraw BL; Banerji A
    J Allergy Clin Immunol Pract; 2017; 5(2):442-447.e1. PubMed ID: 27818136
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.